Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand

Chaimayo, Chutikarn; Kaewnaphan, Bualan; Tanlieng, Nattaya; Athipanyasilp, Niracha; Sirijatuphat, Rujipas; Chayakulkeeree, Methee; Angkasekwinai, Nasikarn; Sutthent, Ruengpung; Puangpunngam, Nattawut; Tharmviboonsri, Theerawoot; Pongraweewan, Orawan; Chuthapisith, Suebwong; Sirivatanauksorn, Yongyut; Kantakamalakul, Wannee; Horthongkham, Navin

doi:10.1186/s12985-020-01452-5

Cited by 275 publications

(273 citation statements)

References 11 publications

(13 reference statements)

Supporting

Mentioning

237

Contrasting

Unclassified

Order By: Relevance

“…To date, several studies have evaluated the diagnostic performance of POCTs in real life, yielding conflicting data. [9][10][11][12][13][14][15][16][17][18][19][20][21] In general, the sensitivity ranged from 60.8% to 79.6%. [13][14][15][16][17][18] Occasionally, significantly high sensitivity (93.9% and 98.3%) has been reported.…”

Section: Discussionmentioning

confidence: 97%

“…[13][14][15][16][17][18] Occasionally, significantly high sensitivity (93.9% and 98.3%) has been reported. [19][20][21] Concerning the Panbio COVID-19 Ag Rapid test (Abbott), the manufacturer reported high sensitivity (93.3%; 95% CI, 83.8-98.2) in a highly endemic setting in Brazil, 22 but other independent cohort studies have not confirmed these data. In 257 symptomatic and asymptomatic patients enrolled at the Emergency Department and Primary Health Care Setting in Spain, the overall sensitivity was 73.3%, reaching 86.5% among patients having symptoms for less than seven days.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

High performance of a novel antigen detection test on nasopharyngeal specimens for diagnosing SARS‐CoV‐2 infection

Courtellemont

Guinard

Guillaume

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has become a major public health issue worldwide. Developing and evaluating rapid and easy-to-perform diagnostic tests is a high priority. The current study was designed to assess the diagnostic performance of an antigen-based rapid detection test (COVID-VIRO ® ) in a real-life setting. Two nasopharyngeal specimens of symptomatic or asymptomatic adult patients hospitalized in the Infectious Diseases Department or voluntarily accessing the COVID-19 Screening Department of the Regional Hospital of Orléans, France, were concurrently collected. The diagnostic specificity and sensitivity of COVID VIRO® results were compared to those of real-time reversetranscriptase quantitative polymerase chain reaction (RT-qPCR) results. A subset of patients underwent an additional oropharyngeal and/or saliva swab for rapid testing. A total of 121 patients confirmed to be infected and 127 patients having no evidence of recent or ongoing infection were enrolled for a total of 248 nasopharyngeal swab specimens. Overall, the COVID-VIRO® sensitivity was 96.7% (CI, 93.5%-99.9%). In asymptomatic patients, symptomatic patients having symptoms for more than 4 days and those with an RT-qPCR cycle threshold value ≥ 32, the sensitivities were 100%, 95.8%, and 91.9%, respectively. The concordance between RT-qPCR and COVID VIRO® rapid test results was 100% for the 127 patients with no SARS-CoV-2 infection. The COVID-VIRO® test had 100% specificity and sensitivity greater than 95%, which are better than the recommendations set forth by the WHO (specificity ≥ 97%-100%, sensitivity ≥ 80%). These rapid tests may be particularly useful for large-scale screening in emergency departments, low-resource settings, and airports.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

High performance of a novel antigen detection test on nasopharyngeal specimens for diagnosing SARS‐CoV‐2 infection

Courtellemont

Guinard

Guillaume

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Thus, the detection of infective SARS-CoV-2 from upper respiratory specimens collected several days prior to symptom onset, lends further evidence for this to be considered to be a possible common feature of mild to asymptomatic COVID-19 infections. There are now several ways to detect the presence of SARS-CoV-2, both with PCR and antigen tests [ 26 , 27 ]. To mitigate the pandemic, early diagnosis is crucial to prevent further transmission.…”

Section: Discussionmentioning

confidence: 99%

Presymptomatic viral shedding and infective ability of SARS-CoV-2; a case report

Nissen

Hagbom

Krambrich

et al. 2021

Heliyon

View full text Add to dashboard Cite

Possible pre- or asymptomatic transmission has been reported, both from SARS-CoV and from MERS-CoV outbreaks, although this appears to be uncommon. In contrast, during the COVID-19 pandemic, an increasing number of studies and case reports indicate that pre- or asymptomatic transmission of SARS-CoV-2 is not only possible but also occurs frequently. We report repeated rRT-PCR detection of SARS-CoV-2 in a health care worker and demonstrate infective ability up to three days prior to mild COVID-19 symptoms. rRT-PCR indicated high viral levels approximately three days after exposure. Viral samples collected one and three days prior to symptoms exhibited infectivity on Vero E6 cells, confirmed by detection of double-stranded RNA by immunofluorescence, assessment of cytopathic effect (CPE) and rRT-PCR. SARS-CoV-2 specific IgM and IgG antibodies were detected by day 9 and 15, respectively, after symptom onset. We propose that this provides evidence for potential early presymptomatic transmission of SARS-CoV-2 and that infectivity may be manifest shortly after exposure.

show abstract

“…The manufacturer claims sensitivity 96.52% (95% CI 91.33-99.04%) and specificity 99.68% (95% CI 98.22 -99.99%) in the test package leaflet [18]. See Supplementary Material S1.3 for a further survey of 10 validation studies [20][21][22][23][24][25][26][27][28][29] with sensitivity median 78.1% and average 78.9%, and specificity median 99.4% and average 98.1%. The sample tested in the mass testing in Slovakia may significantly statistically differ from the validation studies samples.…”

Section: Methodsmentioning

confidence: 99%

Characteristic spatial scales of SARS-CoV-2 pandemics: lessons from mass rapid antigen testing in Slovakia

Boďová

Kollár

2020

Preprint

View full text Add to dashboard Cite

Mass antigen testing in Slovakia conducted in October and November 2020 is a source of important data. We perform its statistical analysis and study epidemic geographical patterns. We observe exponentially distributed test positivity and exponential trends in its geographical distribution, and its approximately 10 km spatial characteristic correlation length. A small correlation between positivity in two consecutive testing rounds appeared on the municipalities level but it significantly increased on the counties level. Recent 7-day PCR tests incidence per capita served as a good proxy for antigen test positivity. Positivity of non-residents was higher than of residents when mass testing was offered only in municipalities with the highest positivity in previous rounds. Reduction in positivity in repeated testing increased with the positivity in the earlier round. Our results contribute to better understanding of pandemic data, and aid an assessment of mass testing efficiency, and planning of mitigation measures.

show abstract

Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand

Cited by 275 publications

References 11 publications

High performance of a novel antigen detection test on nasopharyngeal specimens for diagnosing SARS‐CoV‐2 infection

High performance of a novel antigen detection test on nasopharyngeal specimens for diagnosing SARS‐CoV‐2 infection

Presymptomatic viral shedding and infective ability of SARS-CoV-2; a case report

Characteristic spatial scales of SARS-CoV-2 pandemics: lessons from mass rapid antigen testing in Slovakia

Contact Info

Product

Resources

About